bluebird bio, Inc. (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 1,250 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $95.41, for a total value of $119,262.50. Following the completion of the transaction, the insider now directly owns 28,555 shares of the company’s stock, valued at $2,724,432.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Shares of bluebird bio, Inc. (NASDAQ:BLUE) traded up 2.82% on Monday, reaching $96.60. The company had a trading volume of 427,482 shares. bluebird bio, Inc. has a 52-week low of $37.05 and a 52-week high of $123.75. The company has a 50 day moving average price of $98.08 and a 200 day moving average price of $90.65. The stock’s market capitalization is $4.40 billion.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The business had revenue of $16.70 million for the quarter, compared to analyst estimates of $6.29 million. During the same period in the previous year, the company earned ($1.59) earnings per share. The company’s quarterly revenue was up 977.4% compared to the same quarter last year. On average, equities research analysts anticipate that bluebird bio, Inc. will post ($6.78) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “bluebird bio, Inc. (BLUE) Insider Jeffrey T. Walsh Sells 1,250 Shares” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/bluebird-bio-inc-blue-insider-jeffrey-t-walsh-sells-1250-shares/1488133.html.

A number of research analysts have issued reports on the company. Jefferies Group LLC reissued a “buy” rating and issued a $88.00 price target on shares of bluebird bio in a report on Friday. Morgan Stanley reiterated a “hold” rating on shares of bluebird bio in a research report on Wednesday, August 9th. BidaskClub upgraded bluebird bio from a “sell” rating to a “hold” rating in a research report on Wednesday, August 9th. BMO Capital Markets reiterated a “buy” rating and set a $108.00 price target on shares of bluebird bio in a research report on Friday, August 4th. Finally, Sanford C. Bernstein initiated coverage on bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 price objective on the stock. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $100.66.

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC boosted its stake in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in shares of bluebird bio during the first quarter worth approximately $858,000. Winfield Associates Inc. boosted its position in shares of bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock worth $296,000 after buying an additional 162 shares in the last quarter. Macquarie Group Ltd. acquired a new position in shares of bluebird bio during the fourth quarter worth approximately $703,000. Finally, Alliancebernstein L.P. boosted its position in shares of bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock worth $7,805,000 after buying an additional 28,640 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Insider Buying and Selling by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.